Kanamycin A is an orally available aminoglycoside antibiotic that inhibits bacterial protein synthesis by targeting ribosomal RNA. It is widely used in research applications, including in vitro studies against Mycobacterium tuberculosis and in vivo models of bacterial pneumonia.
